-
Views
-
Cite
Cite
Alessandro Brunelli, Mara B Antonoff, Rene H Petersen, Brendon M Stiles, Dennis A Wigle, Collaborators , Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?, European Journal of Cardio-Thoracic Surgery, Volume 66, Issue 5, November 2024, ezae344, https://doi.org/10.1093/ejcts/ezae344
- Share Icon Share

Proportion of surgeons choosing neoadjuvant chemoimmunotherapy.
chemotherapy, immunotherapy, targeted therapy, surgery, lung cancer, multimodal treatment, neoadjuvant, perioperative, adjuvant
© 2024 The American Association For Thoracic Surgery and European Association for Cardio-Thoracic Surgery. Published by Elsevier Inc on behalf of The American Association For Thoracic Surgery and by Oxford University Press on behalf of European Association for Cardio-Thoracic Surgery. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This paper was jointly developed by The Journal of Thoracic and Cardiovascular Surgery, European Journal of Cardio-Thoracic Surgery and jointly published by Elsevier Inc and Oxford University Press. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
Topic:
- mutation
- chemotherapy regimen
- immunologic adjuvants
- pharmaceutical adjuvants
- non-small-cell lung carcinoma
- combined modality therapy
- immunotherapy
- neoadjuvant therapy
- perioperative care
- epidermal growth factor receptors
- surgical procedures, operative
- surgery specialty
- lung cancer
- molecular targeted therapy
- osimertinib
- programmed cell death 1 ligand 1
- chemoimmunotherapy
Issue Section:
Review
You do not currently have access to this article.